¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"minimal reacting dose"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 3 ÆäÀÌÁö: 1
¿µ¹® radiation dose ÇÑ±Û ¹æ»ç¼±·®
¼³¸í   
  ¹æ»ç¼±Á¶»çÀÇ Á¤µµ. ¹æ»ç¼±»ý¹°ÇÐÀ̳ª ÀÎüÀÇ ¹æ»ç¼±¹æÈ£¿¡¼­´Â Àü¸®¹æ»ç¼±ÀÇ ¾ç, Áï ¼±·®ÀÌ ¹®Á¦°¡ µÈ´Ù. ¹æ»ç¼±·®¿¡¼­µµ ±¹Á¦´ÜÀ§°è(SI)°¡ Ã¤¿ëµÇ¾î ±¹Á¦¹æ»ç¼±¹æÈ£À§¿øÈ¸(ICRP)ÀÇ ±Ç°í¿¡ µû¶ó¼­ ´ÙÀ½ÀÇ ¿©·¯ ´ÜÀ§°¡ ³Î¸® »ç¿ëµÈ´Ù. ¨ç Èí¼ö¼±·®(absorbed dose). ¹°ÁúÀÇ ´ÜÀ§Áú·®ÀÌ ¹æ»ç¼±¿¡ ÀÇÇØ ¹Þ¾ÆµéÀ̴ ¿¡³ÊÁö. ÀÌ ´ÜÀ§´Â ¹æ»ç¼± ¹× ¹°ÁúÀÇ Á¾·ù°¡ ¾î¶°ÇÑ °ÍÀÌ´õ¶óµµ »ç¿ëÇÒ ¼ö ÀÖ´Ù. ±¹Á¦´ÜÀ§´Â J/kgÀ̸ç À̰Ϳ¡ °íÀ¯ÇÑ ¸íĪÀ¸·Î ±×·¹ÀÌ(gray, ±âÈ£ Gy)°¡ ºÎ¿©µÈ´Ù. 1Gy=100¶óµå(rad). ¨è Á¶»ç¼±·®(exposure) ¶Ç´Â °øÁß¼±·®. X¼± ¶Ç´Â ¥ã¼±¿¡ ÇÑÇØ¼­ »ç¿ëµÈ´Ù. ±¹Á¦´ÜÀ§´Â C/kg. ¨é ¼±·®´ç·®(dose equivalent). ¹æ»ç¼±¹æÈ£¸¦ À§ÇØ »ç¿ëµÇ´Â ¾ç. ±âÈ£´Â H. H´Â ¹æ»ç¼±ÀÇ Á¾·ù¿Í ¿¡³ÊÁö¿¡ ÀÇÇØ »ýü¿¡ Áִ ȿ°ú¸¦ º¸Á¤Çϴ ¼±Áú°è¼ö(Q)¿Í ±× ¹ÛÀÇ ÀÎÀÚ(¿¹¸¦ µé¸é ¼±·®·ü, ¹æ»ç¼ºµ¿À§¿ø¼Ò¿¡ ÀÇÇÑ ³»ºÎÇÇÆø½Ã¿¡´Â ±× ÇÙÁ¾ÀǠü³»ºÐÆ÷ µî)¿¡ ±Ù°ÅÇÑ º¸Á¤°è¼ö(N)¸¦ Èí¼ö¼±·®(D)¿¡ °öÇÑ °Í, Áï H=D-Q-N. ¶ÇÇÑ DÀÇ ´ÜÀ§¸¦ Gy ¶Ç´Â rad·Î Ç¥½ÃÇÏ¿´À» ¶§ HÀÇ ´ÜÀ§¸¦ °¢°¢ ½Ãº£¸£Æ®(sievert, ±âÈ£ Sv) ¹× ·½(rem)À̶ó°í ÇÑ´Ù. µû¶ó¼­ 1 Sv=102rem. ÀϹÝÀûÀ¸·Î ´ÜÀ§½Ã°£´çÀÇ ¼±·®À» ¼±·®·ü(dose rate)À̶ó°í ÇÑ´Ù.
¿µ¹® dose ÇÑ±Û ¿ë·®, Åõ¿©·®, ¹æ»ç¼±·®
¼³¸í   
  1. ¾àÁ¦¸¦ ÇÑ ¹ø ¶Ç´Â ÇÏ·ç¿¡ »ç¿ëÇϰųª º¹¿ëÇϴ ºÐ·®. 2. ¹°ÁúÀ̳ª Á¶Á÷¿¡ ´ëÇÑ ¹æ»ç¼±ÀÇ ÀÛ¿ë Á¤µµ¸¦ ³ªÅ¸³»´Â ¾ç. Áï, ¹æ»ç¼±·®À̶ó´Â °³³äÀº ¾î¶² ÇÑ Á¡¿¡ ÀÔ»çÇϴ ¹æ»ç¼±°ú ±× Á¡ ±Ùó¿¡ Àִ ¹°Áú¿¡ ´ëÇÑ ¹æ»ç¼±ÀÇ ¹°¸®Àû-È­ÇÐÀû-»ý¹°ÇÐÀû È¿°ú¿ÍÀÇ °ü°Ô¸¦ Á¤·®ÀûÀ¸·Î ³ªÅ¸³»´Â °øÅëÀΠôµµ·Î¼­ »ý°¢µÈ °ÍÀÌ´Ù. ¶óµå(rad)·Î ³ªÅ¸³»´Â Èí¼ö·®, ·»Æ®°Õ(R)À¸·Î ³ªÅ¸³»´Â Á¶»ç ¼±·®, ·½(rem)À¸·Î ³ªÅ¸³»´Â ¼±·® ´ç·®À¸·Î ±¸ºÐÇÏ¿© ¾´´Ù.
¿µ¹® skin dose ÇÑ±Û ÇǺμ±·®
¼³¸í   
  1. ÇǺÎÇ¥¸é¿¡¼­ÀÇ ¹æ»ç¼±ÀÇ °øÁß¼±·®À¸·Î ¿©±â¿¡´Â 1Â÷¹æ»ç¼±°ú ÈĹæ»ê¶õÀÌ Æ÷ÇԵȴÙ. 2. ÇǺο¡ Èí¼öµÇ´Â ¼±·®.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • reacting dose
    ¹ÝÀÀ¿ë·®
  • minimal effective dose
    ÃÖ¼ÒÀ¯È¿·®
  • minimal erythema dose
    ÃÖ¼ÒÈ«¹Ý¼±·®
  • minimal infecting dose
    ÃÖ¼Ò°¨¿°¿ë·®
  • minimal lethal dose
    1. ÃÖ¼ÒÄ¡»ç·® 2. ÃÖ¼ÒÄ¡»ç¼±·®
  • cross-reacting antibody
    ±³Â÷¹ÝÀÀÇ×ü
  • cross-reacting antigen
    ±³Â÷¹ÝÀÀÇ׿ø
  • cross-reacting material
    ±³Â÷¹ÝÀÀ¹°Áú
  • slow-reacting substance
    Áö¿¬¹ÝÀÀ¹°Áú
  • minimal
    ÃÖ¼Ò-
  • minimal alveolar concentration
    ÃÖ¼ÒÆóÆ÷³óµµ
  • minimal anesthetic concentration
    ÃÖ¼Ò¸¶Ãë³óµµ
  • minimal angle resolution
    ÃÖ¼Ò°¢ºÐÇØ´É
  • minimal bactericidal concentration
    ÃÖ¼Ò»ì±Õ³óµµ
  • minimal blocking concentration
    ÃÖ¼ÒÂ÷´Ü³óµµ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 14 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • minimal invasive surgery
    ÃÖ¼Òħ½À¼ö¼ú
  • dose
    ¿ë·®, Åõ¿©·®, ¹æ»ç¼±·®
  • average dose
    Æò±Õ¿ë·®, Æò±Õ¼±·®
  • booster dose
    Ãß°¡Á¢Á¾·®, Ãß°¡¿ë·®
  • effective dose
    À¯È¿¿ë·®, À¯È¿¼±·®
  • lethal dose
    Ä¡»ç·®
  • maximum dose
    ÃÖ´ë¿ë·®, ÃÖ´ë¼±·®
  • optimum dose
    ÀûÁ¤¿ë·®, ÀûÁ¤¼±·®
  • radiation dose
    ¹æ»ç¼±·®
  • radiation absorbed dose
    Èí¼ö¼±·®
  • skin dose
    ÇǺμ±·®
  • therapeutic dose
    Ä¡·á¿ë·®, Ä¡·á¼±·®
  • high-dose
    °í¿ë·®
  • dose-response relationship
    ¿ë·®¹ÝÀÀ°ü°è
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • reacting dose
    ¹ÝÀÀ¿ë·®
  • minimal effective dose
    ÃÖ¼ÒÀ¯È¿·®
  • minimal erytherma dose
    ÃÖ¼ÒÈ«¹Ý¼±·®
  • minimal lethal dose
    ÃÖ¼ÒÄ¡»ç·®, ÃÖ¼ÒÄ¡»ç¼±·®
  • cross-reacting antibody
    ±³Â÷¹ÝÀÀÇ×ü
  • cross-reacting antigen
    ±³Â÷¹ÝÀÀÇ׿ø
  • cross-reacting material
    ±³Â÷¹ÝÀÀ¹°Áú
  • slow-reacting substance
    Áö¿¬¹ÝÀÀ¹°Áú
  • minimal visible angle
    Ãּҽð¢
  • minimal alveolar concentration
    ÃÖ¼ÒÆóÆ÷³»³óµµ
  • minimal anesthetic concentration
    ÃÖ¼Ò¸¶Ãë³óµµ
  • minimal bactericidal concentration
    ÃÖ¼Ò»ì±Õ³óµµ
  • minimal blocking concentration
    ÃÖ¼ÒÂ÷´Ü³óµµ
  • minimal effective analgesic concentration
    ÃÖ¼ÒÈ¿°úÁøÅë³óµµ
  • minimal inhibitory concentration
    ÃÖÀú¾ïÁ¦³óµµ, ÃÖÀúÀúÁö³óµµ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • reacting dose
    ¹ÝÀÀ·®(ÚãëëåÖ).
  • Kobraks minimal stimulation
    ÄÚºê¶ô¾àÀڱعý
  • SRS A : slow reacting substance A
    ¿¡½º¾Ë¿¡½º-¿¡ÀÌ.
  • antibody, cross-reacting
    ±³Â÷¹ÝÀÀÇ×ü
  • antigen, cross-reacting
    ±³Â÷¹ÝÀÀÇ׿ø
  • ED 50=£¾effective dose 50%
    50% À¯È¿·®, Áß°£À¯È¿·®.
  • ED 50=£¾effective dose 50%
    50% À¯È¿·®.
  • ED 50=ÊÝeffective dose 50%
    50% À¯È¿·®.
  • ED=ÊÝeffective dose
    À¯È¿·®.
  • ID50 (50% infectious dose)
    50% °¨¿°·®
  • LD = lethal dose
    Ä¡»ç·®.
  • LD50 (50% lethal dose)
    50% Ä¡»ç·®
  • LD= lethal dose
    Ä¡»ç·®.
  • MED => minimum effective dose
    ÃÖ¼ÒÈ«¹Ý·®
  • MED=> minimum effective dose
    ÃÖ¼ÒÀ¯È¿·®.
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • minimum reacting dose
    ÃÖ¼Ò¹ÝÀÀ·®(¡­ÚãëëåÖ).
  • reacting dose
    ¹ÝÀÀ·®(ÚãëëåÖ).
  • minimal dose =minimum d.
    ÃÖ¼Ò·®(õÌá³åÖ).
  • minimal effective dose
    ÃÖ¼ÒÀ¯È¿·®.
  • minimal erythema dose
    ÃÖ¼ÒÈ«¹Ý·®(¡­ûõÚèåÖ).
  • minimal erythema dose
    ÃÖ¼ÒÈ«¹Ý·®(¡­ûõÚèåÖ)
  • minimal infecting dose
    ÃÖ¼Ò°¨¿°·®(õÌá³ÊïæøåÖ).
  • minimal lethal dose
    ÃÖ¼ÒÄ¡»ç·®(õÌá´öÈÞÝåÖ).
  • minimal lethal dose
    ÃÖ¼ÒÄ¡»ç·®(̧ËÛ̬Ë×Ëâ).
  • minimal lethal dose
    ÃÖ¼ÒÄ¡»ç·®(õÌá³öÈÞÝåÖ).
  • minimal phototoxicity dose
    ÃÖ¼Ò±¤µ¶·®
  • antibody, cross-reacting
    ±³Â÷¹ÝÀÀÇ×ü
  • antigen, cross-reacting
    ±³Â÷¹ÝÀÀÇ׿ø
  • coagulase-reacting factor
    Ç÷ÀåÀÀ°íÈ¿¼Ò ¹ÝÀÀÀÎÀÚ, ÄھƱֶóÁ¦ ¹ÝÀÀÀÎÀÚ
  • cross reacting antibody
    ±³Â÷¹ÝÀÀÇ×ü(¡­ù÷ô÷).
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • minimal medium
    ÃÖ¼Ò¹èÁö(õÌá³ÛÆò¢)
  • minimal stable length
    ÃÖ¼Ò¾ÈÁ¤(õÌá³äÌïÒ) ±æÀÌ
  • cross-reacting antibody
    ±³Â÷¹ÝÀÀ Ç×ü(Îßó©Úãëëù÷ô÷)
  • cross-reacting antigen
    ±³Â÷¹ÝÀÀ Ç׿ø(Îßó©Úãëëù÷ê«)
  • cross-reacting material
    ±³Â÷¹ÝÀÀ ¹°Áú(Îßó©ÚãëëÚªòõ)
  • slow-reacting substance
    ¿Ï¼Ó(èÐáÜ) ¹ÝÀÀ¹°(ÚãëëÚª)
  • absorbed dose
    Èí¼ö·® (ýåâ¥Õá)
  • air dose
    ´ë±â¼±·®(ÓÞѨàÊÕá)
  • booster dose
    ºÎ½ºÅÍ ·®(Õá)
  • dose-response curve
    ¿ë·®´ëÀÀ °î¼±(é»ÕáÓßëëÍØàÊ)
  • exposure dose
    ³ëÃâ·®(ÖÚõóÕá)
  • fractionated dose
    ºÐÇÒ·®(ÝÂùÜÕá)
  • half-value dose
    ¹Ý(Úâ)°ª ¼±·®(àÊÕá)
  • lethal dose
    Ä¡»ç·®(öÈÞÝÕá)
  • maximum permissible dose
    ÃÖ´ëÇã¿ë·®(õÌÓÞúÉé»Õá)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • minimal effective dose
    ÃÖ¼ÒÀ¯È¿·®
  • minimal
    ÃÖ¼ÒÀÇ
  • minimal enhancement
    ¹Ì¹ÌÇÑÁ¶¿µÁõ°­, °æµµÀÇÁ¶¿µÁõ°­
  • air dose
    °øÁß¼±·®, °ø±âÁß¼±·®
  • cumulative dose
    ÁýÀû¼±·®, ´©ÀûÁ¶»ç·®, ´©Àû¿ë·®, Ãàô¿ë·®
  • curative dose
    ġȿ·®
  • depth dose
    ½ÉºÎ¼±·®
  • dose rate
    ¼±·®·ü
  • fatal dose
    Ä¡»ç·®
  • half lethal dose
    ¹ÝÄ¡»ç·®
  • LD = lethal dose
    Ä¡»ç·®
  • lethal dose [=LD]
    Ä¡»ç·®
  • maintenance dose
    À¯Áö¿ë·®
  • maximal acceptable dose
    ÃÖ´ëÇã¿ë¼±·®
  • maximum permissible dose [=MPD]
    ÃÖ´ëÇã¿ë(¼±)·®
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
MRD maximum rate of depolarization; measles-rindenpest-distemper [virus group]; medical records departme...
ID identification; iditol dehydrogenase; immunodeficiency; immunodiffusion; immunoglobulin deficiency; ...
MPD main pancreatic duct; maximum permissible dose; mean population doubling; membrane potential differe...
TD tabes dorsalis; tardive dyskinesia; T-cell dependent; temporary disability; terminal device; tetanus...
MLD manual lymph drainage; median lethal dose; metachromatic leukodystrophy; minimal lesion disease; min...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
MED Minimal effective dose
MED Minimal Erythema Dose
MPD Minimal phototoxic dose
TBARS 2-thiobarbituric acid-reacting substance
CRD Cross Reacting Determinant
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • minimum reacting dose
    ÃÖ¼Ò ¹ÝÀÀ·®
  • minimal dose
    ÃÖ¼Ò·®
  • coagulase-reacting factor
    Ç÷Àå ÀÀ°í È¿¼Ò ¹ÝÀÀ ÀÎÀÚ
  • cold reacting antibody
    ÇÑ·© Ç×ü
  • warm-reacting autoimmune hemolytic anemia
    »ó¿Â ¹ÝÀÀ¼º ÀÚ°¡ ¸é¿ª¼º ¿ëÇ÷¼º ºóÇ÷, ¿ÂÇ×ü¿¡ ÀÇÇÑ ¿ëÇ÷
    »ó¿Â ¹ÝÀÀ¼º Ç×ü
  • Eagle`s minimal essential medium
    ÀÌ±Û ¹èÁö
    ¼¼Æ÷ ¹è¾ç¾×ÀÇ ÀÏÁ¾. 3Á¾·ùÀÇ ¾Æ¹Ì³ë»ê°ú 8Á¾·ùÀÇ ºñŸ¹ÎÀ» ÇÔÀ¯Çϰí ÀÖÀ¸¸ç º¸Åë Ç÷û 5% ÀÌÇÏ¿¡¼­ À¯Áö ¹èÁö·Î¼­ »ç¿ëµÇ°í 10-20%ÀÇ Ç÷û ÷°¡·Î ¸¹Àº ¼¼Æ÷´Â ±ØÈ÷ ¾çÈ£ÇÑ ¹ßÀ°À» ³ªÅ¸³½´Ù.
  • minimal
    ÃÖ¼ÒÀÇ
    °¡Àå °¡´É¼ºÀÌ ÀûÀº.
  • minimal enhancement
    ¹Ì¹ÌÇÑ Á¶¿µ Áõ°­, °æµµÀÇ Á¶¿µ Áõ°­
  • minimal identifiable odor
    ÃÖ¼Ò ºÐÇØ Ãë°¢
  • minimal requirement
    ÃÖ¼Ò ±Ô°Ý
  • minimal temperature
    ÃÖÀú ¿Âµµ
  • absorbed dose conversion factor
    Èí¼ö¼±·® º¯È¯ °è¼ö
  • air dose
    °øÁß ¼±·®, °ø±âÁß ¼±·®
    ´Ù¸¥ ¹°Ã¼¿¡ ÀÇÇÑ »ê¶õ¼±À» Á¦¿ÜÇÑ °ø±â ÁßÀÇ ¼±·®. ÀϹÝÀûÀ¸·Î ¹°Ã¼ÀÇ Ç¥¸é¿¡ À־µµ, ¶Ç´Â »ýü Á¶Á÷ ³»ÀÇ ÀÏ Á¡¿¡¼­ÀÇ ¼±·®À¸·Î¼­µµ ¸ðµç »ê¶õ¼±ÀÇ ¿µÇâÀ» ¹Þ±â ¶§¹®¿¡ °øÁß ¼±·®º¸´Ù ¸¹¾ÆÁø´Ù.
  • average dose
    Æò±Õ ¿ë·®, Æò±Õ Á¶»ç·®
  • average maintenance dose
    µð±âÅ»¸®½º Æò±Õ À¯Áö·®
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
minimal reacting dose The minimal dose of a toxic substance causing a reaction, as manifested in the skin of a series of susceptible test animals; the assay is based on the development of a characteristic, minimal but definite, "standard," focal inflammation (congestion and oedema, induration, degenerative changes, and desquamation of epidermal cells).
(05 Mar 2000)
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
minimal dose <pharmacology> The smallest amount of a drug or physical procedure that will produce a desired physiologic effect in an adult.
(05 Mar 2000)
minimal infecting dose <microbiology> The smallest quantity of infectious material regularly producing infection; usually expressed as I.D.50, the quantity causing infection in 50% of a suitable series of animals or cells (cell cultures).
(05 Mar 2000)
minimal lethal dose <pharmacology> The minimal dose of a toxic substance or infectious agent that is lethal, as assayed in various experimental animals (e.g., the least amount of diphtheria toxin that, on an average, kills a 250-g guinea pig within 96 hours after subcutaneous inoculation).
When followed by a subscript (generally "MLD50"), denotes the minimal dose that is lethal to a certain percentage (e.g., 50%) of animals so assayed, LD05.
See: lethal dose.
(05 Mar 2000)
cross-reacting agglutinin An immune agglutinin specific for a group antigen.
Synonym: cross-reacting agglutinin.
(05 Mar 2000)
cross-reacting antibody <immunology> Antibody specific for group antigens, i.e., those with identical functional groups, antibody for antigens that have functional groups of closely similar, but not identical, chemical structure.
(05 Mar 2000)
cross-reacting material <haematology> A substance sufficiently different from a reference substance (R) to have a perceptibly different function from R but sufficiently similar to R that it reacts with anti-R antibodies; e.g., mutant factor VIII may be defective or even inert in coagulation and yet be immunologically identified as factor VIII.
(05 Mar 2000)
slow-reacting factor of anaphylaxis Slow-reacting substance of anaphylaxis (SRS-A), a leukotriene of low molecular weight which is released in anaphylactic shock and produces slower and more prolonged contraction of muscle than does histamine; it is active in the presence of antihistamines (but not epinephrine) and seems not to occur preformed in mast cells, but as a result of an antigen-antibody reaction on the granules.
Compare: peptidyl leukotrienes.
Synonym: slow-reacting factor of anaphylaxis.
(05 Mar 2000)
slow-reacting substance Slow-reacting substance of anaphylaxis (SRS-A), a leukotriene of low molecular weight which is released in anaphylactic shock and produces slower and more prolonged contraction of muscle than does histamine; it is active in the presence of antihistamines (but not epinephrine) and seems not to occur preformed in mast cells, but as a result of an antigen-antibody reaction on the granules.
Compare: peptidyl leukotrienes.
Synonym: slow-reacting factor of anaphylaxis.
(05 Mar 2000)
slow reacting substance of anaphylaxis <immunology> Potent bronchoconstrictor and inflammatory agent released by mast cells, an important mediator of allergic bronchial asthma.
A mixture of three leukotrienes (LTC4 mainly, LTD4 and LTE4)
(18 Nov 1997)
direct reacting bilirubin The fraction of serum bilirubin which has been conjugated with glucuronic acid in the liver cell to form bilirubin diglucuronide; so called because it reacts directly with the Ehrlich diazo reagent; increased levels are found in hepatobiliary diseases, especially of the obstructive variety.
Synonym: conjugated bilirubin.
(05 Mar 2000)
indirect reacting bilirubin The fraction of serum bilirubin which has not been conjugated with glucuronic acid in the liver cell; so called because it reacts with the Ehrlich diazo reagent only when alcohol is added; increased levels are found in hepatic disease and haemolytic conditions.
Synonym: unconjugated bilirubin.
(05 Mar 2000)
minimal Smallest or least, the smallest possible.
Origin: L. Minimus = least
(18 Nov 1997)
minimal air The volume of gas that remains in the lungs and cannot be expelled after they have been removed from the body, or after the chest has been opened.
(05 Mar 2000)
minimal alveolar concentration The end-alveolar concentration of an inhalation anaesthetic which prevents somatic response to a painful stimulus in 50% of individuals; an index of relative potency of inhalation anaesthetics.
Synonym: minimal anaesthetic concentration.
(05 Mar 2000)
minimal amplitude nystagmus Nystagmus of so small an amplitude that it is not detected by the usual clinical tests.
Synonym: minimal amplitude nystagmus.
Origin: micro-+ G. Nystagmos, a nodding
(05 Mar 2000)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 9 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • chain-reacting pile
    ¿¬¼â¹ÝÀÀ·Î;¿øÀÚ·Î
  • dose
    ¾àÀÇ 1ȸºÐ;~¿¡ Åõ¾àÇÏ´Ù;º¹¿ë½ÃŰ´Ù
  • maximum dose
    (¾àÀÇ) ±Ø·®
  • minimum dose
    ÃÖ¼Ò Åõ¾à·®
  • minimal
    ±Ø¼ÒÀÇ; ÃÖÀúÀÇ
  • minimal
    ÃÖ¼ÒÇâ(¼ö)ÀÇ;±Ø¼ÒÀÇ
  • minimal art
    ¹Ì´Ï¸Ö ¾ÆÆ®;ÃÖ¼ÒÇÑÀÇ Á¶Çü ¼ö´ÜÀ¸·Î Á¦ÀÛµÈ ±×¸²;Á¶°¢
  • minimal brain dysfunction
    ¹Ì¼Ò ³ú±â´É Àå¾Ö (¾Æµ¿ÀÇ ÇнÀ Àå¾ÖÀÇ Çϳª)
  • minimal pair
    ÃÖ¼Ò ´ë¾î(bet¿Í bed ó·³ °°Àº À§Ä¡ÀÇ ÇÑ °¡Áö ¼Ò¸®¸¸ ´Ù¸¥ ÇÑ ½ÖÀÇ ³¹¸»)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
ÅëÇÕ°Ë»ö ¿Ï·á